A Review on Mucormycosis with recent pharmacological treatment
Abstract
Mucormycosis is antifungal eye infection difficult to manage this infection with limited use of diagnostic tool and therapeutic option, but previous literature studied diagnostic strategies and evaluate the potency of antifungal agent as a treatment option. Mucormycosis was difficult to study on imaging studies. Surgery plus antifungal therapy of high dose yields greater survival rates. Mucorales are most widely resisted to the used as an antifungal agent. Amphotericin -B were kept for de-escalation refractory therapy whereas, patient’s intolerant to Amphotericin B.
Keywords: Mucormycosis, amphotericin, antifungal agents
Keywords:
Mucormycosis, amphotericin, antifungal agentsDOI
https://doi.org/10.22270/jddt.v11i3-S.4844References
Global guideline for the diagnosis and management of Mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study group Education and research Consortium. Lancet infect Dis.2019; 19(12):405-421. https://doi.org/10.1016/S1473-3099(19)30312-3
Bearer E. A, P.R. Nelson, M.Y. Chowers and C.E. Davis. Cutaneous Zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J. Clin. Microbiol 1994; 32:1823-1824. https://doi.org/10.1128/jcm.32.7.1823-1824.1994
Kamalam A., and A.S. Thambiah. Cutaneous infection by Syncephalastrum. Sabouraudia 1980; 18:19-20. https://doi.org/10.1080/00362178085380051
Bitar D., Lortholary O., Le strat Y., et al.: Population based analysis of invasive fungal infection. Emerg Infect Dis.2014; 20:1149-1155. https://doi.org/10.3201/eid2007.140087
Ribes J.A., Vanover Sam's C.L., Baker D.J., Zygomycetes in human Disease. Clin Microbiol Rev.2000; 13: 236-301. https://doi.org/10.1128/CMR.13.2.236
Chinn R.Y and R.D. Diamond. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophiles and effects of hyperglycemia and ketoacidosis. Infect Immun. 1982; 38: 1123-1129. https://doi.org/10.1128/iai.38.3.1123-1129.1982
Diamond R.D., Haudenschild and N.F. Erickson 3rd. Monocyte mediated damage to Rhizopus oryzae hyphae in vitro. Infect. Immun. 1982; 38:292-297. https://doi.org/10.1128/iai.38.1.292-297.1982
Waldorf A.R. Pulmonary defense mechanism against opportunistic fungal pathogens. Immunol ser.1989; 47:243-247.
Waldorf A.R., Ruderman N., and R.D. diamond. Specific susceptibility to Mucormycosis in murine diabetes and bronchoalveolar macrophages defense against Rhizopus J. Clin.Investig.1984; 74:150-162. https://doi.org/10.1172/JCI111395
Boelaert J.R., M. delocht., J. Van Cutsem., V. Kerrels., B. Cantinieaux., A. Verdonck, H.W. Van Landuyt et al., Mucormycosis during deferoxamine therapy is a siderophore mediated infection. In vitro and in vivo animal studies. J. Clin. Investig.19963; 91:1979-1986. https://doi.org/10.1172/JCI116419
Abe F., H. Inaba., T. Katoh and M. Hotchi. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia.1990; 110:87-91. https://doi.org/10.1007/BF00446996
Artis W.M., Fountain H.K., Delcher H.E. Jones. A Mechanism of Susceptibility to Mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes.1982; 31:1109- 1114. https://doi.org/10.2337/diacare.31.12.1109
Ribes J.A., Vanover Sam's C.L. and D.J. Baker. Zygomycetes in human disease.Clin.Microbiol.Rev.2000; 13:236-301. https://doi.org/10.1128/CMR.13.2.236
Bouchara J.P., N.A. Oumeziane, J.C. Lissitzzky, G.Larcher, G.Tronchin, and D. Chabasse.Attchement od spores of the human pathogenic fungus Rhizopus Oryzae to extracellular matrix components. Eur.J. Cell Biol. 1996; 70:76-83.
Nussbaum E.S and W.A. Hall. Rhinocerebral Mucormycosis: changing patterns of disease. Surg. Neurol. 1994; 41:152-156. https://doi.org/10.1016/0090-3019(94)90114-7
Kwon-Chung K.J., J.E. Bennett. Medical Mycology, Lea & febiger,Philadelphia, 1992; 524-559.
Nissen M.D., A.K. Jana, M.J. Cole., J.M. Grierson and G.L. Gillbert. Neonatal gastrointestinal Mucormycosis mimicking necrotizing enterocolitis. Acta Paediatr. 1999; 88:1290-1293. https://doi.org/10.1111/j.1651-2227.1999.tb01035.x
Ribes J. A, C.L.Vanover- Sam's and D.J. Baker.Zygomycetes in human disease. Clin.Microbiol.Rev.13:236-301. https://doi.org/10.1128/CMR.13.2.236
Ibrhim A.S., J.E.J. Edwards and S.G. Filler. In W. E. Dismukes P.G. Pappas and J.D. Sobel, Clinical mycology. Oxford University Press, New York. 2003; 241-251.
Larsen K.C., Von Buchwald B., Ellefsen, D. Francis.Unexpected expensive paranasal sinus Mucormycosis. Orl J.Otorhinolaryngol.Relat.Spec. 2003; 65:57-60. https://doi.org/10.1159/000068657
Camara-lemarroy CR, Gonzalez-moreno EI, Rodriguez Gutierrez R., et al., Clinical feature and outcome of Mucormycosis. Interdiscip Perpect Infect Dis.2014; 14:562-610. https://doi.org/10.1155/2014/562610
Kim YI, Kang HC, Lee HS, et al., Invasion pulmonary Mucormycosis with concomitant lung cancer presented with massive hemoptysis by huge pseudoaneurysm of pulmonary artery. Ann thorac Surg., 2014; 98:1832-1835. https://doi.org/10.1016/j.athoracsur.2013.12.051
Kontoyiannis DP., Lewis RE., Invasive Zygomycosis: Update on pathogenesis, clinical manifestation, and management. Infect Dis. Clin North Am. 2006; 20: 581-607. https://doi.org/10.1016/j.idc.2006.06.003
Walsh T.J., Gamaletsou MN., Mc Ginnis MR., Hayden R.T., Kontoyiannis D.P., Early Clinical and Laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated Mucormycosis. Clin Infect Dis. 2012; 54:555-560. https://doi.org/10.1093/cid/cir868
Petrikkos G., Skiada A., Lortholary O., Roilidews E., Walsh T. J, Kontoyaiannins D. P, Epidemiology and clinical manifestation of Mucormycosis. Clin Infect Dis.2012; 54:523-534. https://doi.org/10.1093/cid/cir866
Vironneau P., Kania R., Morizot G., Local control of rhino-orbito-cerebral Mucormycosis dramatically impacts survival .Clin Microbiol Infect. 2004; 20:336-339. https://doi.org/10.1111/1469-0691.12408
Cornely OA, Arikan-Akdagli S., Dannaoui E., et.al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of Mucormycosis. Clin Microbiol Infect. 2014; 20:5-26. https://doi.org/10.1111/1469-0691.12371
Chamilos G., Lewis RE., Kontaoyiannins DP, Delaying amphotericin B-Based frontline therapy significantly increase mortality among patient with hematologic malignancy who have Zygomycosis. Clin Infect Dis. 2008; 47:503-509. https://doi.org/10.1086/590004
Skiada A., Pangano L., Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of medical Mycology working group on Zygomycosis between 2005 and 2007.clin Microbiol Infect. 2011; 17:1859-1867. https://doi.org/10.1111/j.1469-0691.2010.03456.x
Almyroudis NG., Sutton DA., Fothergill AW, Rinaldi MG., Kunsne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents chemother.2007; 51:2587-2590. https://doi.org/10.1128/AAC.00452-07
Petrikkos G., A. Skiada H., Sambatakou A., Toskas G., Vaiopoulos M., Giannopoulou and N. Katsilambros. Mucormycosis: ten-year experience at a tertiary care centre in Greece. Eur. J. Clin. Microbiol. Infect Dis. 2003; 22:753-756. https://doi.org/10.1007/s10096-003-1035-y
Waldorf A.R. and R.D. Diamond. Cerebral Mucormycosis in diabetic mice after intrasinus challenges. infect.Immun.1984; 44:194-199. https://doi.org/10.1128/iai.44.1.194-195.1984
Waldorf A.R., N. Ruderman and R.D. Diamond. Specific susceptibility to Mucormycosis in murine diabetes and bronchoalveolar macrophages defense against Rhizopus J.Clin.Investig.1984; 74:150-160. https://doi.org/10.1172/JCI111395
Dannaoui E., J.F.Meis D., Loebenberg and P.E.Verweij. Activity of Posaconazole in treatment of experimental disseminated Zygomycosis. Antimicrob. Agents chemother.2003; 47:3647-3650. https://doi.org/10.1128/AAC.47.11.3647-3650.2003
Ibrahim A.S., J.E. Edwards and S.G. Filler Zygomycosis. In W.E. Dismukes P.G., Pappas and J.D.Sobel ., Clinical mycology. Oxford university press. New York.2003; 241-251.
Kwon-chung, K.J. and J.E.Bennett. Medical mycology. Lea & Febiger, Philadelphia, 1992, 524-559.
Spellberg B., M.D. Witt and C.K. Beck. Amphotericin B: is a lipid -formulation gold standard feasible. Clin Infect Dis.2004; 38:304-307. https://doi.org/10.1086/380844
Sun Q.N., A.W. Fothergill, D. I Mccarthy, M.G. Rinaldiand J.R.Graybill. in vitro activities of Posaconazole, itraconzole, voriconazole, amphotericin B and fluconazole against 37 clinical isolates of zygomycetes. antimicrob. Agents Chemother.2002; 46:1581-1582. https://doi.org/10.1128/AAC.46.5.1581-1582.2002
Weng D.E., W.H. Wilson R. Little T.J. Walsh. Successful medical management of isolated renal Zygomycosis: case report and review. Clin. Infect.Dis.1998; 26:601-605. https://doi.org/10.1086/514562
Quinio D., A. Karam, J. P. Leroy, M. C. Moal, B. Bourbigot,O. Masure, B.Sassolas. and A.M. Le Flohic. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med. Mycol.2004; 42:177-180. https://doi.org/10.1080/13693780310001644644
Rickert V., A. Bohme and G. just Nubling. Risk factor for invasive Zygomycosis in patients with hematologic malignancies. Mycoses.2002; 45:27-30. https://doi.org/10.1111/j.1439-0507.2002.tb04542.x
Del Poeta M., W.A. Schell and J.R. Perfect. In vitro antifungal activity of pneumocandian L-743-872 against a variety of clinically important moulds. Antimicrob. Agents Chemother.1997; 41:1835-1836. https://doi.org/10.1128/AAC.41.8.1835
Abzug M.J., T.J.Walsh . Interferon-gamma and colony stimulating factors as adjuvant therapy for refractory fungal infection in children.pediatr.infect.Dis.2004; 23:769-773. https://doi.org/10.1097/01.inf.0000134314.65398.bf
Garcia-Covarrubias L., D.M. Barratt, R. Bartlett and K. Van Meter. Treatment of Mucormycosis with adjunctive hyperbaric oxygen: five cases treated at the same institution and review of the literature. Rev.Investig. Clin.2004; 56:51-55
Published
Abstract Display: 607 
PDF Downloads: 683 PDF Downloads: 43 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.